Video

Dr. Goodman on the Need for Molecular Subtyping in T-Cell Lymphomas

Aaron Goodman, MD, discusses the need for molecular subtyping in T-cell lymphomas.

Aaron Goodman, MD, hematologist/oncologist and assistant professor of medicine at the University of California, San Diego, discusses the need for molecular subtyping in T-cell lymphomas.

Investigators should keep T-cell lymphomas separate from other lymphomas in clinical trials, says Goodman. Ideally, there would be separate trials for patients with specific subtypes of T-cell lymphomas as well, adds Goodman.

As more information regarding the genetic makeup of T-cell lymphoma emerges, focused research efforts on more specific patient populations may inform which therapies are best suited for each patient, says Goodman.

For example, patients with angioimmunoblastic T-cell lymphoma appear to have better responses to hypomethylating agents and histone deacetylase inhibitors compared with other types of T-cell lymphoma, says Goodman.

The identification of molecular subtypes in acute myeloid leukemia led to the development of targeted therapies. Similarly, molecular subtyping in T-cell lymphoma may be important in moving the needle forward, concludes Goodman.

Related Videos
Noa Biran, MD
Andrew Hantel, MD
Peter Forsyth, MD
Jakub Svoboda, MD
Joaquim Bellmunt, MD, PhD
María-Victoria Mateos, MD, PhD
Ponatinib in patients with chronic-phase chronic myeloid leukemia and the T315I mutation: 4-year results from OPTIC
John L. Marshall, MD
Petros Grivas, MD, PhD
Noopur S. Raje, MD